HER2低表达乳腺癌：现状与未来展望
HER2-Low Breast Cancer: Current Landscape and Future Prospects.
作者信息
Shirman Yelena, Lubovsky Shlomit, Shai Ayelet
机构信息
Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
出版信息
Breast Cancer (Dove Med Press). 2023 Aug 14;15:605-616. doi: 10.2147/BCTT.S366122. eCollection 2023.
Abstract
More than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. In most studies that compared the clinical and biological characteristics of HER2-low BC with HER2-negative BC, HER2-low was not associated with unique clinical and molecular characteristics, and it seems that the importance of HER2 in these tumors is being a docking site for the antibody portion of antibody drug conjugates (ADCs). Current pathological methods may underestimate the proportion of BCs that express low levels of HER2 due to analytical limitations and tumor heterogeneity. In this review we summarize and contextualize the most recent literature on HER2-low breast cancers, including clinical and translational studies We also review the challenges of assessing low HER2 expression in BC and discuss the current and future therapeutic landscape for these tumors.
摘要
目前，超过50%的乳腺癌被定义为“人表皮生长因子受体2（HER2）低表达乳腺癌（BC）”，其HER2免疫组化（IHC）评分为+1或+2，荧光原位杂交（FISH）检测为阴性。在大多数比较HER2低表达BC与HER2阴性BC临床和生物学特征的研究中，HER2低表达与独特的临床和分子特征无关，而且HER2在这些肿瘤中的重要性似乎在于它是抗体药物偶联物（ADC）抗体部分的对接位点。由于分析局限性和肿瘤异质性，目前的病理方法可能会低估HER2低表达BC的比例。在这篇综述中，我们总结并梳理了关于HER2低表达乳腺癌的最新文献，包括临床和转化研究。我们还回顾了评估BC中HER2低表达的挑战，并讨论了这些肿瘤当前和未来的治疗前景。
相似文献
1
HER2-Low Breast Cancer: Current Landscape and Future Prospects.HER2低表达乳腺癌：现状与未来展望
Breast Cancer (Dove Med Press). 2023 Aug 14;15:605-616. doi: 10.2147/BCTT.S366122. eCollection 2023.
2
Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer.HER2低表达乳腺癌的当前生物学、病理学及临床概况
Cancers (Basel). 2022 Dec 25;15(1):126. doi: 10.3390/cancers15010126.
3
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.HER2 低表达乳腺癌——来自正在进行的研究的诊断挑战和见解：播客。
Target Oncol. 2023 May;18(3):313-319. doi: 10.1007/s11523-023-00964-8. Epub 2023 May 3.
4
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.曲妥珠单抗药物偶联物治疗领域的不断发展：HER2 阳性乳腺癌以外的未来前景。
Cancer Treat Rev. 2023 Feb;113:102500. doi: 10.1016/j.ctrv.2022.102500. Epub 2022 Dec 24.
5
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.针对人表皮生长因子受体 2 低表达乳腺癌的开放性问题、当前挑战和未来展望。
ESMO Open. 2024 Apr;9(4):102989. doi: 10.1016/j.esmoop.2024.102989. Epub 2024 Apr 12.
6
HER2-Low Breast Cancer: a New Subtype?HER2 低表达乳腺癌：一种新亚型？
Curr Treat Options Oncol. 2023 May;24(5):468-478. doi: 10.1007/s11864-023-01068-1. Epub 2023 Mar 27.
7
The HER2-low revolution in breast oncology: steps forward and emerging challenges.乳腺癌肿瘤学中的HER2低表达革命：进展与新出现的挑战
Ther Adv Med Oncol. 2023 Feb 9;15:17588359231152842. doi: 10.1177/17588359231152842. eCollection 2023.
8
Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.人表皮生长因子受体2（HER2）低表达状态对早期乳腺癌新辅助化疗反应的影响
Cureus. 2022 Feb 17;14(2):e22330. doi: 10.7759/cureus.22330. eCollection 2022 Feb.
9
Challenges in HER2-low breast cancer identification, detection, and treatment.HER2低表达乳腺癌在识别、检测和治疗方面的挑战。
Transl Breast Cancer Res. 2024 Jan 11;5:3. doi: 10.21037/tbcr-23-48. eCollection 2024.
10
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.在 HER2 阳性乳腺癌中实施抗体药物偶联物 (ADC)：现状和未来方向。
Breast Cancer Res. 2021 Aug 11;23(1):84. doi: 10.1186/s13058-021-01459-y.
引用本文的文献
1
Discordance in Immunohistochemistry Results in Breast Pathologies: Effect of Chemotherapy, Specimen Characteristics, or Pathology Center?乳腺病理中免疫组织化学结果的不一致性：化疗、标本特征或病理中心的影响？
Clin Med Insights Oncol. 2025 Aug 20;19:11795549251367498. doi: 10.1177/11795549251367498. eCollection 2025.
2
Educational case: Estrogen-receptor positive breast cancer: Diagnosis, response to therapy, and prognosis.教学案例：雌激素受体阳性乳腺癌：诊断、治疗反应及预后
Acad Pathol. 2025 Aug 12;12(3):100210. doi: 10.1016/j.acpath.2025.100210. eCollection 2025 Jul-Sep.
3
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.早期浸润性小叶乳腺癌患者中HER2低表达与临床病理特征的相关性：一项国际多中心研究
Breast Cancer Res. 2025 Jun 13;27(1):106. doi: 10.1186/s13058-025-02058-x.
4
Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type.HER2低表达在高级别特殊组织学类型及非特殊类型三阴性乳腺癌中的预后影响
PLoS One. 2025 Jun 13;20(6):e0325715. doi: 10.1371/journal.pone.0325715. eCollection 2025.
5
Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy.接受CDK4/6抑制剂和激素疗法治疗的HER2低表达转移性乳腺癌患者的治疗模式和结局
Drugs Context. 2025 May 7;14. doi: 10.7573/dic.2024-12-1. eCollection 2025.
6
Development and clinical evaluation of [Ga]Ga-NODAGA-ADAPT6 as a novel HER2-targeted PET radiotracer for breast cancer imaging and treatment monitoring.[镓]Ga-NODAGA-ADAPT6作为一种新型HER2靶向PET放射性示踪剂用于乳腺癌成像和治疗监测的研发与临床评估。
Eur J Nucl Med Mol Imaging. 2025 Apr 21. doi: 10.1007/s00259-025-07286-z.
7
Redefining therapeutic landscapes: clinicopathological insights into low and ultra-low HER2 expression in male breast cancer.重新定义治疗格局：男性乳腺癌中低水平和超低水平HER2表达的临床病理见解
Diagn Pathol. 2025 Apr 15;20(1):43. doi: 10.1186/s13000-025-01632-3.
8
Advanced and Metastatic Triple Negative Breast Cancer-Potential New Treatment.晚期及转移性三阴性乳腺癌——潜在的新疗法
Cancers (Basel). 2025 Mar 31;17(7):1183. doi: 10.3390/cancers17071183.
9
Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies.乳腺癌的分子亚型与机制：靶向治疗的精准医学方法
Cancers (Basel). 2025 Mar 25;17(7):1102. doi: 10.3390/cancers17071102.
10
Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.接受新辅助治疗的HER2低表达与HER2零表达早期乳腺癌患者的病理缓解率：一项系统评价和荟萃分析
Breast Cancer Res. 2025 Mar 15;27(1):39. doi: 10.1186/s13058-025-01989-9.
本文引用的文献
1
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.人表皮生长因子受体 2 检测在乳腺癌中的应用：ASCO-美国病理学家学会指南更新。
J Clin Oncol. 2023 Aug 1;41(22):3867-3872. doi: 10.1200/JCO.22.02864. Epub 2023 Jun 7.
2
Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer.转移性乳腺癌中 HER2 低状态的患者内和转移间异质性。
Eur J Cancer. 2023 Jul;188:152-160. doi: 10.1016/j.ejca.2023.04.026. Epub 2023 May 6.
3
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test.HER2低表达乳腺癌的病理诊断：优化检测的技巧、窍门及故障排除
Front Mol Biosci. 2023 Apr 3;10:1176309. doi: 10.3389/fmolb.2023.1176309. eCollection 2023.
4
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.国家癌症数据库中 ERBB2 低表达乳腺癌患者的临床病理特征和预后。
JAMA Oncol. 2023 Apr 1;9(4):500-510. doi: 10.1001/jamaoncol.2022.7476.
5
The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.人工智能在准确解读乳腺癌HER2免疫组化评分0和1+中的作用
Mod Pathol. 2023 Mar;36(3):100054. doi: 10.1016/j.modpat.2022.100054. Epub 2023 Jan 10.
6
Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2-low breast cancer.HER2评分显示的数字图像分析和辅助判读降低了一致性：HER2低表达乳腺癌分类中的陷阱
Histopathology. 2023 May;82(6):912-924. doi: 10.1111/his.14877. Epub 2023 Mar 1.
7
Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression.HER2 的泛素化抑制其蛋白降解并促进乳腺癌进展。
Int J Biol Sci. 2023 Jan 1;19(2):377-392. doi: 10.7150/ijbs.75852. eCollection 2023.
8
Improving HER2 testing reproducibility in HER2-low breast cancer.提高HER2低表达乳腺癌中HER2检测的可重复性。
Cancer Drug Resist. 2022 Sep 1;5(4):882-888. doi: 10.20517/cdr.2022.29. eCollection 2022.
9
Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors.通过人工智能确定HER2状态：对原发性、转移性和HER2低表达乳腺肿瘤的研究
Diagnostics (Basel). 2023 Jan 3;13(1):168. doi: 10.3390/diagnostics13010168.
10
HER2-Low Status Is Not Accurate in Breast Cancer Core Needle Biopsy Samples: An Analysis of 5610 Consecutive Patients.HER2低表达状态在乳腺癌粗针穿刺活检样本中并不准确：对5610例连续患者的分析。
Cancers (Basel). 2022 Dec 15;14(24):6200. doi: 10.3390/cancers14246200.
Zotero 插件